Sutro Biopharma Reports Third Quarter 2024 Financial Results and ...

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights · Comments Section · Community Info Section · More posts you ...

Sutro Biopharma, Inc - BioSpace

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights. November 14, 2024. ·. 10 min read. Press Releases · Sutro Biopharma ...

EX-99.1 - SEC.gov

Exhibit 99.1. Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones.

Vaxcyte Reports First Quarter 2024 Financial Results and Provides ...

Cash Position: Cash, cash equivalents and investments were $1,899.8 million as of March 31, 2024, compared to $1,242.9 million as of December 31, 2023. The ...

STRO SEC Filings - Sutro Biopharma, Inc.- Annual Report, Proxy ...

Press Releases (Most Recent) ; 2023-08-10, Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones).

Day One Reports Third Quarter 2024 Financial Results and ...

Strong growth in OJEMDA net revenue with $20.1M in the third quarter of 2024, representing a 145% increase over the second quarter of 2024. Quarterly ...

Sutro Biopharma, Inc. Common Stock (STRO) Earnings Report Date

none raised and none lowered their forecast. For the fiscal year ending Dec 2024 , the consensus EPS* forecast has remained the same over the past week at -2.96 ...

Sutro Biopharma Inc. filed SEC Form 8-K: Results of Operations and ...

On November 13, 2024, Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended ...

SUTRO BIOPHARMA, INC. SEC 10-Q Report - TradingView

Total Revenue: $8.5 million for Q3 2024, compared to $16.9 million for Q3 2023. · Loss from Operations · Net Loss · Net Loss Per Share, basic and ...

Sutro Biopharma, Inc. (STRO) Stock Price, Quote & News

In 2023, Sutro Biopharma's revenue was $153.73 million, an increase of 126.84% compared to the previous year's $67.77 million. Losses were -$106.79 million, - ...

Sutro Biopharma Reports Third Quarter 2023 Financial Results ...

Total operating expenses for the quarter ended September 30, 2023 were $60.9 million, as compared to $46.4 million for the same period in 2022.

STRO - Sutro Biopharma, Inc. Latest Stock News & Market Updates

Financially, Sutro reported cash and investments totaling $321.1 million and an additional $34.0 million in Vaxcyte common stock as of September 30, 2023, ...

STRO | Sutro Biopharma Inc. Financial Statements - WSJ

-0.73 Q3 2024, Qtr. Year Ago -0.81 Q3 2023. Ann. EPS Est. -3.88 FY 2024, Ann. Year Ago -2.35 FY 2022. Next Report 11/07/2024 ... 5-quarter trend. Net Income ...

Sutro Biopharma Stock Price Today | NASDAQ: STRO Live

Revenue for the quarter came in at $8.5M... Investing.com; 46 minutes ago. Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights.

Sutro Biopharma Reports First Quarter 2024 Financial Results ...

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones · $899 million in upfront and ...

Financial Information - Sutro Biopharma, Inc.

Financial Info. Overview · Financial Results · Income Statement · Balance Sheet · Cash Flow. Latest Financial Results. Q2 2024. Quarter Ended Jun 30, 2024.

Vaxcyte Reports Third Quarter 2024 Financial Results and

General & Administrative (G&A) Expenses: G&A expenses were $23.0 million for the three months ended September 30, 2024, as compared to $15.6 ...

Sutro Biopharma Reports Second Quarter 2022 Financial Results ...

runway into the first half of 2024, based on current business plans and assumptions. ... third parties and other risks and uncertainties ...

Passage Bio Reports Third Quarter 2024 Financial Results and ...

Research and Development (R&D) Expenses: R&D expenses were $8.7 million for the quarter ended September 30, 2024, as compared to $15.1 million ...

TriSalus Reports Q3 2024 Financial Results and Provides Business ...

TriSalus Reports Q3 2024 Financial Results and Provides Business Update · $7.3 million and · $21.2 million , respectively, for the three and nine ...